Comparison study on the effect of prenatal administration of high dose and low folic acid

Saudi Medical Journal

Volumn 30, Issue 1, 2009, Pages 88-97

  Manizheh, Sayyah M ^a   Mandana, Shojaiee ^a   Hassan, Argani ^a   Amir, Gorbani H ^a   Mahlisha, Kazemi S ^a   Morteza, Ghojazadeh ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; FOLIC ACID; HOMOCYSTEINE; LACTATE DEHYDROGENASE; URIC ACID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINO ACID BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE URINE LEVEL; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG MEGADOSE; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; PREECLAMPSIA; PREGNANCY; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE COUNT; UREA BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; HYPERTENSION; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PREGNANCY TRIMESTER, FIRST; SINGLE-BLIND METHOD;

EID: 62849101602     PISSN: 03795284     EISSN: 16583175     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Martin JA, Hamilton BE, Ventura SJ, Menacker F, Park MM. Births: Final data for 2000. Hyattsville, (MD): US Department of Health and Human Services, CDC, National Center for Health Statistics; 2002. National vital statistics reports No. 5.
2. Berg CJ, Chang J, Callaghan WM, Whitehead SJ. Pregnancy-related mortality in the United State, 1991-1997. Obstet Gynecol 2003; 101; 289-296.
3. COG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 2002; 77: 67-75.
4. Dekker GA, de Vries JI, Doelitzsch PM, Huijgens PC, von Blomberg BM, Jakobs C, et al. Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol 1995; 173: 1042-1048.
5. Roberts JM, Speer P. Antioxidant therapy to prevent preeclampsia. Semin Nephrol 2004; 24: 557-564.
6. Milman N, Bergholt T, Byg KE, Eriksen L, Hvas AM. Reference intervals for haematological variables during normal pregnancy and postpartum in 434 healthy Danish women. Eur J Haematol 2007; 79: 39-46.
7. Cikot RJ, Steegers-Theunissen RP, Thomas CM, de Boo TM, Merkus HM, Steegers EA, et al. Longitudinal vitamin and homocysteine levels in normal pregnancy. Br J Nutr 2001; 85: 49-58.
8. Walker M, Smith G, Perkins S, Keely E, Garner P. Changes in homocysteine levels during normal pregnancy. Am J Obstet Gynecol 1999; 180: 660-664.
9. Murphy MM, Scott JM, McPartlin JM, Fernandez-Ballart JD. The pregnancy-related decrease in fasting plasma homocysteine is not explained by folic acid supplementation, hemodilution, or a decrease in albumin in a longitudinal study. Am J Clin Nutr 2002; 76: 614-619.
10. Cotter AM, Molloy AM, Scott JM, Daly SF. Elevated plasma homocysteine in early pregnancy: A risk factor for the development of severe preeclampsia. Am J Obstet Gynecol 2001; 185: 781-785.
11. Cotter AM, Molly AM, Scott JM, Daly SF. Elevated plasma homocysteine in early pregnancy: A risk factor for the development of nonsevere preeclampsia. Am J Obstet Gynecol 2003; 189: 391-394.
12. D'Anna R, Baviera G, Corrado F, Ientile R, Granese D, Stella NC. Plasma homocysteine in early and late pregnancies complicated with preeclampsia and isolated intrauterine growth restriction. Acta Obstet Gynecol Scand 2004; 83: 155-158.
13. Zeeman GG, Alexander JM, McIntire DD, Devaraj S, Leveno KJ. Homocysteine plasma concentration levels for the prediction of preeclampsia in women with chronic hypertension. Am J Obstet Gynecol 2003; 189: 574-576.
14. Gatt A, Makris M. Hyperhomocysteinemia and venous thrombosis. Semin Hematol 2007; 44: 70-76.
15. Nadir Y, Hoffman R, Brenner B. Association of homocysteine, vitamin B12, folic acid, and MTHFR C677T in patients with a thrombotic event or recurrent fetal loss. Ann Hematol 2007; 86: 35-40.
16. McKay DL, Berkowitz JM, Blumberg JB, Goldberg JP. Communicating cardiovascular disease risk due to elevated homocysteine levels: Using the EPPM to develop print materials. Health Educ Behav 2004; 31: 355-371.
17. Hoffman ML, Scoccia B, Kurczynski TW, Shulman LP, Gao W. Abnormal folate metabolism as a risk factor for first-trimester spontaneous abortion. J Reprod Med 2008; 53: 207-212.
18. Homocysteine Lowering Trialists' Collaboration. Dose-dependent effects of folic acid on blood concentrations of homocysteine: A meta-analysis of the randomized trials. Am J Clin Nutr 2005; 82: 806-812.
19. Bodnar LM, Tang G, Ness RB, Harger G, Roberts JM, Periconceptional multivitamin use reduces the risk of preeclampsia. Am J Epidemiol 2006; 164: 470-477.
20. Jyothi S, Misra I, Morris G, Benton A, Griffin D, Allen S. Red cell folate and plasma homocysteine in preterm infants. Neonatology 2007; 92: 264-268.
21. Taparia S, Gelineau-van Waes J, Rosenquist TH, Finnell RH. Importance of folate-homocysteine homeostasis during early embryonic development. Clin Chem Lab Med 2007; 45: 1717-1727.
22. Ashworth JR, Warren AY, Johnson IR, Baker PN. Plasma from pre-eclamptic women and functional change in myometrial resistance arteries. Br J Obstet Gynaecol 1998; 105: 459-461.
23. Graham IM, Daly LE, Refsum HM, Robinson K, Brattström LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997; 277: 1775-1781.
24. Ray JG, Laskin CA. Folic acid and homocysteine metabolic defects and the risk of placenta abruption, pre-eclampsia and spontaneous pregnancy loss: A systematic review. Placenta 1999; 20: 519-529.
25. Massé J, Giguère Y, Kharfi A, Girouard J, Forest JC. Pathophysiology and maternal biologic markers of preeclampsia. Endocrine 2002; 19: 113-125.
26. Olthof MR, Bots ML, Katan MB, Verhoef P. Effect of folic acid and betaine supplementation on flow-mediated dilation: A randomized, controlled study in healthy volunteers. PLoS Clin Trials 2006; 1: 10.
27. Vollset SE, Refsum H, Irgens LM, Emblem BM, Tverdal A, Gjessing HK. Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: The Hordaland homocysteine study. Am J Clin Nutr 2000; 71: 962-968.
28. Holmes VA, Ward M, et al. Homocysteine is lower in the third trimester of pregnancy in women with enhanced folate status from continued folic acid supplementation. Clin Chem 2005; 51: 629-634.
29. Rajkovic A, Mohamed K, Malinow MR, Sorenson TK, Woelk GB, Williams MA. Plasma homocyst(e)ine concentration in eclamptic and preeclamptic African women postpartum. Obstet Gynecol 1999; 94: 355-360.
30. López-Quesada E, Vilaseca MA, Lailla JM. Plasma total homocysteine in uncomplicated pregnancy and in preeclampsia. Eur J Obstet Gynecol Reprod Biol 2003; 108: 45-49.
31. Noris M, Perico N, Remuzzi G. Mechanisms of disease: Preeclampsia. Nat Clin Pract Nephrol 2005; 1: 98-114.
32. Van Pampus MG, Dekker GA, Wolf H, Huijgens PC, Koopman MM, von Blomberg BM, et al. High prevalence of haemostatic abnormalities in women with a history of severe preeclampsia. Am J Obstet Gynecol 1999; 180: 1146-1150.
33. Wang J, Trudinger BJ, Duarte N, Wilcken DE, Wang XL. Elevated circulating homocysteine levels in placental vascular disease and associated preeclampsia. BJOG 2000; 107: 935-938.
34. McKinley MC. Nutritional aspects and possible pathological mechanisms of hyperhomocysteinaemia: An independent risk factor for vascular disease. Proc Nutr Soc 2000; 59: 221-237.
35. Makedos G, Papanicolaou A, Hitoglu A, Kalogiannidis I, Makedos A, Vrazioti V, et al. Homocysteine, folic acid, and B12 serum levels in pregnancy complicated with preeclampsia. Arch Gynecol Obstet 2007; 275: 121-124.
36. de Vries JI, Dekker GA, Huijgens PC, Jakobs C, Blomberg BM, van Geijn HP. Hyperhomocysteinemia and protein S deficiency in complicated pregnancies. Br J Obstet Gynaecol 1997; 104: 1248-1254.
37. Powers RW, Dunbar MS, Gallaher MJ, Roberts JM, The 677 C-T methylenetetrahydrofolate reductase mutation does not predict increased maternal homocysteine during pregnancy. Obstet Gynaecol 2003; 101: 762-766.
38. Domagala TB, Undas A, Libura M, Szczeklik A. Pathogenesis of vascular disease in hyperhomcysteinemia. J Cardiovasc Risk 1998; 5: 239-247.
39. Hague WM. Homocysteine and pregnancy. Best Prac Res Clin Obstet Gynaecol 2003; 17: 459-469.
40. Stover PJ. Influence of human genetic variation on nutritional requirements. Am J Clin Nutr 2006; 83: 436-442.
41. Biselli JM, Goloni-Bertollo EM, Zampieri BL, Haddad R, Eberlin MN, Pavarino-Bertelli EC. Genetic polymorphisms involved in folate metabolism and elevated plasma concentrations of homocysteine: Maternal risk factors for Down syndrome in Brazil. Genet Mol Res 2008; 7: 33-42.
42. Afman LAm Trijbels FJ, Blom HJ. The H475Y polymorphism in the glutamate carboxypeptidase II gene increases plasma folate without affecting the risk for neural tube defects in humans. J Nutr 2003; 133: 75-77.
43. Silaste ML, Rantala M, Sämpi M, Alfthan G, Aro A. Kesäniemi YA. Polymorphisms of key enzymes in homocysteine metabolism affect diet responsiveness of plasma homocysteine in healthy women. J Nutr 2001; 131: 2643-2647.
44. Cronin S, Furie KL, Kelly PJ. Dose related association of MTHFR 677T allele with risk of ischemic stroke: Evidence from a cumulative meta-analysis. Stroke 200; 36: 1581-1587.
45. Davis SR, Quinlivan EP, Shelnutt KP, Maneval DR, Ghandour H, Capdevila A, et al. The methylenetetrahydrofolate reductase 677C->T polymorphism and dietary folate restriction affect plasma one-carbon metabolites and red blood cell folate concentrations and distribution in women. J Nutr 2005; 135: 1040-1044.
46. Kluijtmans LAJ, Young IS, Boreham CA, Murray L, McMaster D, McNulty H, et al. Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults. Blood 2003; 101: 2483-2488.
47. Järvenpää J, Schwab U, Lappalainen T, Päkkilä M, Niskanen L, Punnonen K, et al. Fortified mineral water improves folate status and decreases plasma homocysteine concentration in pregnant women. J Perinat Med 2007; 35: 108-114.
48. Fernández M, Fernández G, Diez-Ewald M, Torres E, Vizcaíno G, Fernández N, et al. Plasma homocysteine concentration and its relationship with the development of preeclampsia. Effect of prenatal administration of folic acid. Invest Clin 2005; 46: 187-195.
49. Eskes TK, Clotting disorders and placental abruption: Homocysteine-a new risk factor. Eur J Obstet Gynecol Reprod Biol 2001; 95: 206-212.
50. Achon M, Alonso-Aperte E, Reyes L, Ubeda N, Varela-Moreiras G. High-dose folic acid supplementation in rats: Effects on gestation and the methionine cycle. Br J Nutr 2000; 83: 177-183.
51. Mills JL, Signore CC. Quinlivan EP, Gregory JF, Czeizel AE, Wald NJ. Folic Acid and the Prevention of Neural-Tube Defects. N Engl J Med 2004; 350: 2209-2211.
52. Venn BJ, Green TJ, Moser R, Mann JI. Comparison of the effect of low-dose supplementation with L-5-methyltetrahydrofolate or folic acid on plasma homocysteine: A randomized placebo-controlled study. Am J Clin Nutr 2003; 77: 658-662.
53. Charles DH, Ness AR, Campbell D, Smith GD, Whitley E, Hall MH. Folic acid supplements in pregnancy and birth outcome: Re nalysis of a large randomised controlled trial and update of Cochrane review. Paediatr Perinat Epidemiol 2005; 19: 112-124.
54. Wen SW, Chen XK, Rodger M, White RR, Yang Q, Smith GN, et al. Folic acid supplementation in early second trimester and the risk of preeclampsia. Am J Obstet Gynecol 2008; 198: 45.
55. Bolander-Gouaille C. The homocysteine metabolism. Focus on homocysteine and the vitamins involved in its metabolism. 2nd ed. Paris (FR): Springer; 2002. p. 20.
56. Lachmeijer AM, Arngrímsson R, Bastiaans EJ, Pals G, ten Kate LP, de Vries JI, et al. Mutation in the gene for methylenetetrahydrofolate reductase, homocysteine levels and vitamin status in women with history of preeclampsia. Am J Obstet Gynecol 2004; 184: 394-402.
57. Mignini LE, Latthe PM, Villar J, Kilby MD, Carroli G, Khan KS. Mapping the theories of preeclampsia: The role of homocysteine. Obstet Gynecol 2005; 105: 411-425.
58. Powers RW, Evans RW, Majors AK, Ojimba JI, Ness RB, Crombleholme WR, et al. Plasma homocysteine concentration is increased in preeclampsia and is associated with evidence of endothelial activation. Am J Obstet Gynecol 1998; 179: 1606-1611.
59. Wallace JM, Bonham MP, Strain J, Duffy EM, Robson PJ, Ward M, et al. Homocysteine concentration, related B vitamins, and betaine in pregnant women recruited to the Seychelles Child Development Study. Am J Clin Nutr 2008; 87: 391-397.
60. López-Quesada EL, Vilaseca MA, González S. Homocysteine and pregnancy. Med Clin (Barc) 2000; 115: 352-356.
61. Verkleij-Hagoort AC, Verlinde M, Ursem NT, Lindemans J, Helbing WA, Ottenkamp J, et al. Maternal hyperhomocysteinaemia is a risk factor for congenital heart disease. BJOG 2006; 113: 1412-1418.
62. Verkleij-Hagoort AC, de Vries JH, Ursem NT, de Jonge R, Hop WC, Steegers-Theunissen RP. Dietary intake of B-vitamins in mothers born a child with a congenital heart defect. Eur J Nutr 2006; 45: 478-486.
63. Brown AS, Bottiglieri T, Schaefer CA, Quesenberry CP Jr, Liu L, Bresnahan M, et al. Elevated prenatal homocysteine levels as a risk factor for schizophrenia. Arch Gen Psychiatry 2007; 64: 31-39.
64. Wals DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002; 325:1202.
65. Czeizel AE, Tímár L, Sárközi A. Dose-dependent effect of folic acid on the prevention of orofacial clefts. Pediatrics 1999; 104: E66.
66. Mills JL, Von Kohorn I, Conley MR, Zellet JA, Cox C, Williamson RE, et al. Low vitamin B-12 concentration in patients without anemia: The effect of folic acid fortification of grain. Am J Clin Nutr 2003; 77: 1474-1477.
67. Smith AD, Kim YI, Refsum H. Is folic acid good for everyone? Am J Clin Nutr 2008; 84: 517-533.
68. Leeda M, Riyazi N, de Vries JI, Jakobs C, van Geijn HP, Dekker GA. Effects of folic acid and vitamin B6 supplementation on women with hyperhomocysteinemia and a history of preeclampsia or fetal growth restriction. Am J Obstet Gynecol 1998; 179: 135-139.
69. Barton JR, Sibai BM. Prediction and prevention of recurrent preeclampsia. Obstet Gynecol 2008; 112: 359-372.
70. Steegers-Theunissen RP, Van Iersel CA, Peer PG, Nelen WL, Steegers EA. Hyperhomocysteinemia, pregnancy complications, and the timing of investigation. Obstet Gynecol 2004; 104: 336-343.